Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab vs Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
NCT03150875Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2017
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in squamous cell carcinoma of the lung (LSCC), sponsored by Innovent Biologics. Started Sep 2017; status: completed.
02
Drugs
sintilimab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT03150875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150875.